A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability.
Vascular endothelial growth factor (VEGF) induces both angiogenesis and an increase in vascular permeability, 2 processes that are considered to be important for both tumor growth and the delivery of drugs to the site of tumors. This study demonstrates that transmembrane expression of tumor necrosis factor (tmTNF) is up-regulated in the endothelium of a murine methylcholanthrene (meth A)-induced sarcoma in comparison to the adjacent normal dermal vasculature and is also present on cultivated human endothelial cells. It is further shown that tmTNF is required for VEGF-mediated endothelial hyperpermeability in vitro and in vivo. This permissive activity of TNF appears to be selective, because anti-TNF antibodies ablated the VEGF-induced permeability but not proliferation of cultivated human endothelial cells. Furthermore, tnf gene-deficient mice show no obvious defects in vascularization and develop normally but failed to respond to administration of VEGF with an increase in vascular permeability. Subsequent studies indicated that the tmTNF and VEGF signaling pathways converge at the level of a secondary messenger, the "stress-activated protein kinase-2" (SAPK-2)/p38: (1) up-regulated endothelial expression of tmTNF resulted in the continuous activation of SAPK-2/p38 in vitro, and (2) an inhibitor of SAPK-2/p38 activation abolished the vascular permeability activity of VEGF in vivo. In conclusion, the study's finding that continuous autocrine signaling by tmTNF sensitizes endothelial cells to respond to VEGF by increasing their vascular permeability provides new therapeutic concepts for manipulating vascular hyperpermeability.
Clauss
M
M
Department of Molecular Cell Biology, Max-Planck-Institute, Bad Nauheim, Germany. m.clauss@kerchoff.mpg.de
Sunderkötter
C
C
Sveinbjörnsson
B
B
Hippenstiel
S
S
Willuweit
A
A
Marino
M
M
Haas
E
E
Seljelid
R
R
Scheurich
P
P
Suttorp
N
N
Grell
M
M
Risau
W
W
D000818:Animals; D019898:Autocrine Communication / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects*; D004151:Dipeptides / Q000494:pharmacology; D016228:Endothelial Growth Factors / Q000378:metabolism / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000737:chemistry / Q000166:cytology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007150:Immunohistochemistry; D008222:Lymphokines / Q000378:metabolism / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000494:pharmacology / Q000502:physiology; D008748:Methylcholanthrene; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000139:chemically induced; D013925:Thromboplastin / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D014470:Umbilical Cord / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D004151:Dipeptides; D016228:Endothelial Growth Factors; D006877:Hydroxamic Acids; D008222:Lymphokines; D008562:Membrane Glycoproteins; C092152:N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide; D009363:Neoplasm Proteins; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008748:Methylcholanthrene; D013925:Thromboplastin